Introduction: NSAIDs inhibit COX-2, which is responsible for regulating neurons leading to neurodegeneration in Alzheimer’s disease. Alzheimer’s disease is a neurodegenerative disease affecting the geriatric population, as it affects more than two third cases of dementia in the sphere. Results obtained from experimental and observational studies were unclear regarding the protective role of NSAIDs in AD, therefore this justifies the need for meta-analysis. Methods: Database search was PubMed, Web of Science, and Embase. Experimental studies and Observational studies investigating the effect of NSAIDs on AD. For experimental studies indicators used were MMSE score, ADAS-cog score, CDR-sob score, NPI score, and Hazard ratio. Similarly for Observational studies, Odds Ratio and Relative Risk are used. Results: As this is the study protocol, therefore it is not possible to write the results of the study in the study protocol. There is a total of 06 (MMSE, ADAS-cog, CDR-sob, HR, RR, and OR) indicators used in the study, so 06 results will be obtained showing the pooled effect size which will indicate the use of NSAIDs as a protective factor for Alzheimer’s disease. Discussion: The present systematic review will improve the understanding of the relative efficacies of NSAIDs in AD and possibly guide clinical practices by providing the current best evidence on the efficacy of various regimens of NSAIDs in the management of AD subjects. Conclusion: Conclusion can be drawn only after the final meta-analysis using three study design (RCT, Cohort and Case-control study designs) and six indicators.
References
[1]
Aisen, P.S., Schmeidler, J. and Pasinetti, G.M. (2002) Randomized Pilot Study of Nimesulide Treatment in Alzheimer’s Disease. Neurology, 58, 1050-1054. https://doi.org/10.1212/WNL.58.7.1050
[2]
CDC Newsroom (2016) U.S. Burden of Alzheimer’s Disease, Related Dementias to Double by 2060. https://www.cdc.gov/media/releases/2018/p0920-alzheimers-burden-double-2060.html
[3]
Prince, M., Wimo, A., Guerchet, M., Ali, G.C., Wu, Y.T. and Prina, M. (2015) World Alzheimer Report 2015. The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends.
[4]
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W. and Ferri, C.P. (2013) The Global Prevalence of Dementia: A Systematic Review and Metaanalysis. Alzheimer’s & Dementia Journal, 9, 63-75. https://doi.org/10.1016/j.jalz.2012.11.007
[5]
Wu, Y.T., et al. (2017) The Changing Prevalence and Incidence of Dementia over Time—Current Evidence. Nature Reviews Neurology, 13, 327-339. https://doi.org/10.1038/nrneurol.2017.63
[6]
Miguel-álvarez, M., et al (2015) Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect. Drugs & Aging, 32, 139-147. https://doi.org/10.1007/s40266-015-0239-z
[7]
Talwar, P., et al. (2016) Dissecting Complex and Multifactorial Nature of Alzheimer’s Disease Pathogenesis: A Clinical, Genomic, and Systems Biology Perspective. Molecular Neurobiology, 53, 4833-4864. https://doi.org/10.1007/s12035-015-9390-0
[8]
Reines, S.A., et al. (2004) Rofecoxib: No Effect on Alzheimer’s Disease in a 1-Year, Randomized, Blinded, Controlled Study. Neurology, 62, 66-71. https://doi.org/10.1212/WNL.62.1.66
[9]
Thal, L.J., et al. (2005) A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment. Neuropsychopharmacology, 30, 1204-1215. https://doi.org/10.1038/sj.npp.1300690
[10]
Cai, Y., Liu, J., Wang, B., Sun, M. and Yang, H. (2022) Microglia in the Neuroinflammatory Pathogenesis of Alzheimer’s Disease and Related Therapeutic Targets. Frontiers in Immunology, 13, Article ID: 856376. https://doi.org/10.3389/fimmu.2022.856376
[11]
Cagnin, A., et al. (2001) In-vivo Measurement of Activated Microglia in Dementia. The Lancet, 358, 461-467. https://doi.org/10.1016/S0140-6736(01)05625-2
[12]
Veronese, N., et al. (2017) Low-Dose Aspirin Use and Cognitive Function in Older Age: A Systematic Review and Meta-Analysis. Journal of the American Geriatrics Society, 65, 1763-1768. https://doi.org/10.1111/jgs.14883
[13]
Scarpini, E., Scheltens, P. and Feldman, H. (2003) Treatment of Alzheimer’s Disease: Current Status and New Perspectives. The Lancet Neurology, 2, 539-547. https://doi.org/10.1016/S1474-4422(03)00502-7
[14]
Etminan, M., Gill, S. and Samii, A. (2003) Effect of Non-Steroidal Anti-Inflammatory Drugs on Risk of Alzheimer’s Disease: Systematic Review and Meta-Analysis of Observational Studies. BMJ, 327, Article 128. https://doi.org/10.1136/bmj.327.7407.128
[15]
Zhou, Y., Boudreau, D.M. and Freedman, A.N. (2014) Trends in the Use of Aspirin and Nonsteroidal Anti-Inflammatory Drugs in the General U.S. Population. Pharmacoepidemiology and Drug Safety, 23, 43-50. https://doi.org/10.1002/pds.3463
[16]
Aisen, P.S., et al. (2003) Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial. JAMA, 289, 2819-2826. https://doi.org/10.1001/jama.289.21.2819
[17]
McGeer, P.L., Schulzer, M. and McGeer, E.G. (1996) Arthritis and Anti-Inflammatory Agents as Possible Protective Factors for Alzheimer’s Disease: A Review of 17 Epidemiologic Studies. Neurology, 47, 425-432. https://doi.org/10.1212/WNL.47.2.425
[18]
Stewart, W.F., Kawas, C., Corrada, M. and Metter, E.J. (1997) Risk of Alzheimer’s Disease and Duration of NSAID Use. Neurology, 48, 626-632. https://doi.org/10.1212/WNL.48.3.626
[19]
Hamrick, I., Hafiz, R. and Cummings, D.M. (2013) Use of Days of the Week in a Modified Mini-Mental State Exam (M-MMSE) for Detecting Geriatric Cognitive Impairment. The Journal of the American Board of Family Medicine, 26, 429-435. https://doi.org/10.3122/jabfm.2013.04.120300
[20]
Kleinbaum, D.G. and Klein, M. (2012) Survival Analysis: A Self-Learning Text. 3rd Edition, Springe, New York. https://doi.org/10.1007/978-1-4419-6646-9
[21]
Haidich, A.B. (2010) Meta-Analysis in Medical Research. Hippokratia, 14, 29-37.
[22]
(2022) Cochrane Handbook for Systematic Reviews of Interventions—Google Books. https://books.google.co.in/books?hl=en&lr=&id=cTqyDwAAQBAJ&oi=fnd&pg=PR3&dq=cochrane+handbook+for+systematic+reviews+of+interventions.+Chichester,+hoboken:+wiley-blackwell%3B2008&ots=tvkIxaCGkg&sig=oJVFFeSEkbCy1S6n90qkkAXc1QU#v=onepage&q&f=false
[23]
Higgins, J.P.T., et al. (2011) The Cochrane Collaboration’s Tool for Assessing Risk of Bias in Randomised Trials. BMJ, 343, d5928. https://doi.org/10.1136/bmj.d5928
[24]
Parmar, M.K., Torri, V. and Stewart, L. (1998) Extracting Summary Statistics to Perform Meta-Analyses of the Published Literature for Survival Endpoints. Statistics in Medicine, 17, 2815-2834. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
[25]
Berger, V.W. and Alperson, S.Y. (2009) A General Framework for the Evaluation of Clinical Trial Quality. Reviews on Recent Clinical Trials, 4, 79-88. https://doi.org/10.2174/157488709788186021
[26]
Dwivedi, S.N. (2017) Which Is the Preferred Measure of Heterogeneity in Meta-Analysis and Why? A Revisit. Biostatistics and Biometrics Open Access Journal, 1, 14-20. https://doi.org/10.19080/BBOAJ.2017.01.555555
[27]
Lo, C.K.L., Mertz, D. and Loeb, M. (2014) Newcastle-Ottawa Scale: Comparing Reviewers’ to Authors’ Assessments. BMC Medical Research Methodology, 14, Article No. 45. https://doi.org/10.1186/1471-2288-14-45
[28]
(2022) Introduction to Meta-Analysis Reviews & Ratings. Buy Introduction to Meta-Analysis Book Online at Low Prices in India. https://www.amazon.in/Introduction-Meta-Analysis-Michael-Borenstein/dp/0470057246
[29]
Reiman, E.M., et al. (2012) Brain Imaging and Fluid Biomarker Analysis in Young Adults at Genetic Risk for Autosomal Dominant Alzheimer’s Disease in the Presenilin 1 E280A Kindred: A Case-Control Study. The Lancet Neurology, 11, 1048-1056. https://doi.org/10.1016/S1474-4422(12)70228-4
[30]
Szekely, C.A., et al. (2008) NSAID Use and Dementia Risk in the Cardiovascular Health Study: Role of APOE and NSAID Type. Neurology, 70, 17-24. https://doi.org/10.1212/01.wnl.0000284596.95156.48
[31]
Hayden, K.M., et al. (2007) Does NSAID Use Modify Cognitive Trajectories in the Elderly? The Cache County Study. Neurology, 69, 275-282. https://doi.org/10.1212/01.wnl.0000265223.25679.2a
[32]
ADAPT Research Group (2007) Naproxen and Celecoxib Do Not Prevent AD in Early Results from a Randomized Controlled Trial. Neurology, 68, 1800-1808. https://doi.org/10.1212/01.wnl.0000260269.93245.d2
[33]
Breitner, J.C., et al. (2011) Extended Results of the Alzheimer’s Disease Anti-Inflammatory Prevention Trial. Alzheimer’s & Dementia Journal, 7, 402-411. https://doi.org/10.1016/j.jalz.2010.12.014
[34]
Ruitenberg, A., et al. (2001) Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer’s Disease. The New England Journal of Medicine, 345, 1515-1521. https://doi.org/10.1056/NEJMoa010178
[35]
Wichmann, M.A., et al. (2016) NSAID Use and Incident Cognitive Impairment in a Population-Based Cohort. Alzheimer Disease & Associated Disorders, 30, 105-112. https://doi.org/10.1097/WAD.0000000000000098
[36]
Xue, Y.H. et al. (2018) Etoricoxib and Diclofenac Might Reduce the Risk of Dementia in Patients with Osteoarthritis: A Nation-Wide, Population-Based Retrospective Cohort Study. Dementia and Geriatric Cognitive Disorders, 45, 262-271. https://doi.org/10.1159/000485176
[37]
Aizen, E., Kagan, G., Assy, B., Iobel, R., Bershadsky, Y. and Gilhar, A. (2005) Effect of Non-Steroidal Anti-Inflammatory Drugs on Natural Killer Cell Activity in Patients with Dementia. Israel Medical Association Journal, 7, 78-81.
[38]
Lindsay, J., et al. (2002) Risk Factors for Alzheimer’s Disease: A Prospective Analysis from the Canadian Study of Health and Aging. American Journal of Epidemiology, 156, 445-453. https://doi.org/10.1093/aje/kwf074
[39]
Vlad, S.C., Miller, D.R., Kowall, N.W., and Felson, D.T. (2008) Protective Effects of NSAIDs on the Development of Alzheimer Disease. Neurology, 70, 1672-1677. https://doi.org/10.1212/01.wnl.0000311269.57716.63
[40]
Dregan, A., Chowienczyk, P. and Armstrong, D. (2015) Patterns of Anti-Inflammatory Drug Use and Risk of Dementia: A Matched Case-Control Study. European Journal of Neurology, 22, 1421-1428. https://doi.org/10.1111/ene.12774
[41]
Landi, F., Cesari, M., Onder, G., Russo, A., Torre, S. and Bernabei, R. (2003) Non-Steroidal Anti-Inflammatory Drug (NSAID) Use and Alzheimer Disease in Community-Dwelling Elderly Patients. The American Journal of Geriatric Psychiatry, 11, 179-185. https://doi.org/10.1097/00019442-200303000-00008
